NCT07233655

A Phase II Trial of SHR-3045 Injection in Patients With Rheumatoid Arthritis

A Randomized, Double-blind, Placebo-controlled Phase IIa Study to Evaluate the Efficacy and Safety of SHR-3045 Injection in Patients With Moderate to Severe Active Rheumatoid Arthritis

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This study is ongoing to explore the efficacy and safety of different strengths of SHR-3045 injection in moderate to severe active rheumatoid arthritis.

Conditions

• Moderate to Severe Active Rheumatoid Arthritis

Interventions

Type	Name	Description
DRUG	SHR-3045 Injection	SHR-3045 injection.
DRUG	SHR-3045 Injection Placebo	SHR-3045 injection placebo.

Timeline

• Start date: 2026-01-19
• Primary completion: 2026-07-01
• Completion: 2026-07-01
• First posted: 2025-11-18
• Last updated: 2026-03-05

Locations

1 site across 1 country: China